Samran Sheriff

Dr. Samran Sheriff

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2025 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SSSamran Sheriff
Samran Sheriff
MSMaree Saba
Maree Saba
RPRomika Patel
Romika Patel
GFGeorgia Fisher
Georgia Fisher
TSTanja Schroeder
Tanja Schroeder
LELouise Ann Ellis
Louise Ann Ellis
Background: Liquid biopsy (LB) offers a promising, minimally invasive alternative to traditional tissue biopsies in cancer care, enabling real-time monitoring and personalized treatment. Despite its potential, the routine implementation of LB in clinical practice faces significant challenges. This scoping review examines the barriers and facilitators influencing the implementation of liquid biopsies into standard cancer care. Methods: Four academic databases (PubMed, Scopus, Embase, and Web of Science) were systematically searched without language restrictions. We included peer-reviewed articles that were published between January 2019 and March 2024 that focused on the implementation of LB in cancer care or described barriers and facilitators to its implementation. Data relevant to the review objective, including key article characteristics; barriers and facilitators of implementation; and recommendations for advancement or optimisation; were extracted and analysed using thematic and visual network analyses. Results: The majority of the included articles were narrative review articles (84%), with most from China (24.2%) and the United States (20%). Thematic analysis identified four main categories and their associated barriers and facilitators to the implementation of LB in cancer care: (1) Laboratory and personnel requirements; (2) Disease specificity; (3) Biomarker-based liquid biopsy; and (4) Policy and regulation. The majority of barriers identified were concentrated in the pre-analytical phase, highlighting the lack of standardization in LB technologies and outcomes. Conclusions: Through a thematic analysis of the barriers and facilitators to LB implementation, we present an integrated tool designed to encourage the standardization of testing methods for clinical practice guidelines in the field.

31 July 2021 in Cells
Verified
Journal Article
Open access
PDF file
NCNitin Chitranshi
Nitin Chitranshi
AKAshutosh Kumar
Ashutosh Kumar
SSSamran Sheriff
Samran Sheriff
VGVeer Gupta
Veer Gupta
AGAngela Godinez
Angela Godinez
Vivek GuptaVivek Gupta
Vivek Gupta
Amyloid precursor protein (APP), upon proteolytic degradation, forms aggregates of amyloid β (Aβ) and plaques in the brain, which are pathological hallmarks of Alzheimer’s disease (AD). Cathepsin B is a cysteine protease enzyme that catalyzes the proteolytic degradation of APP in the brain. Thus, cathepsin B inhibition is a crucial therapeutic aspect for the discovery of new anti-Alzheimer’s drugs. In this study, we have employed mixed-feature ligand-based virtual screening (LBVS) by integrating pharmacophore mapping, docking, and molecular dynamics to detect small, potent molecules that act as cathepsin B inhibitors. The LBVS model was generated by using hydrophobic (HY), hydrogen bond acceptor (HBA), and hydrogen bond donor (HBD) features, using a dataset of 24 known cathepsin B inhibitors of both natural and synthetic origins. A validated eight-feature pharmacophore hypothesis (Hypo III) was utilized to screen the Maybridge chemical database. The docking score, MM-PBSA, and MM-GBSA methodology was applied to prioritize the lead compounds as virtual screening hits. These compounds share a common amide scaffold, and showed important interactions with Gln23, Cys29, His110, His111, Glu122, His199, and Trp221. The identified inhibitors were further evaluated for cathepsin-B-inhibitory activity. Our study suggests that pyridine, acetamide, and benzohydrazide compounds could be used as a starting point for the development of novel therapeutics.

15 March 2023 in Neural Regeneration Research
Verified
Journal Article
Open access
SSSamran Sheriff
Samran Sheriff
TSTing Shen
Ting Shen
SASandra Abdal
Sandra Abdal
DSDanit Saks
Danit Saks
MMMehdi Mirzaei
Mehdi Mirzaei
Vivek GuptaVivek Gupta
Vivek Gupta
Examining the retinal tissue has the potential to provide a unique method and technique to quantify Alzheimer's disease-related changes in participants at various stages of the disease. In this meta-analysis, we aimed to investigate the association of various optical coherence tomography parameters with Alzheimer's disease and whether retinal measurements can be used to differentiate between Alzheimer's disease and control subjects. Scientific databases including Google Scholar, Web of Science, and PubMed were systematically searched for published articles that evaluated retinal nerve fiber layer thickness and retinal microvascular network in Alzheimer's disease and control subjects. Seventy-three studies (5850 participants, including 2249 Alzheimer's disease patients and 3601 controls) were included in this meta-analysis. Relative to controls, Alzheimer's disease patients had a significantly lower global retinal nerve fiber layer thickness (standardized mean difference [SMD] = -0.79, 95% confidence intervals [CI]: -1.03 to -0.54, P < 0.00001) as well as each quadrant being thinner in Alzheimer's disease versus controls. Regarding macular parameters, values measured by optical coherence tomography were significantly lower in Alzheimer's disease than controls for macular thickness (pooled SMD: -0.44, 95% CI: -0.67 to -0.20, P = 0.0003), foveal thickness (pooled SMD = -0.39, 95% CI: -0.58 to -0.19, P < 0.0001), ganglion cell inner plexiform layer (SMD = -1.26, 95% CI: -2.24 to -0.27, P = 0.01) and macular volume (pooled SMD = -0.41, 95% CI -0.76 to -0.07, P = 0.02). Analysis using optical coherence tomography angiography parameters revealed mixed results between Alzheimer's disease and controls. Superficial vessel density (pooled SMD = -0.42, 95% CI: -0.68 to -0.17, P = 0.0001) and deep vessel density (pooled SMD = -0.46, 95% CI: -0.75 to -0.18, P = 0.001) were found to be thinner in Alzheimer's disease patients whereas the foveal avascular zone (SMD = 0.84, 95% CI: 0.17-1.51, P = 0.01) was larger in controls. Vascular density and thickness of various retinal layers were decreased in Alzheimer's disease patients compared to controls. Our results provide evidence for optical coherence tomography technology having the potential to detect retinal and microvascular changes in patients diagnosed with Alzheimer's disease and aid in monitoring and early diagnosis methods.

27 September 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SSSamran Sheriff
Samran Sheriff
TSTing Shen
Ting Shen
DSDanit Saks
Danit Saks
ASAngela Schultz
Angela Schultz
HFHeather Francis
Heather Francis
Vivek GuptaVivek Gupta
Vivek Gupta
Purpose: To investigate the relationship between the apolipoprotein E (APOE) ε4 allele and retinal structural and vascular characteristics in older adult participants from several research studies. We also studied the relationship between these structural and vascular characteristics with multifocal visual evoked potential (mfVEP) indices, neuropsychological parameters and MRI brain volumes in these participants. Methods: In this study, 109 participants with a mean (SD) age of 67.1 (9.0) years were recruited. Participants were classified as APOE ε4 carriers or non-carriers based on the presence or absence of the ε4 allele. Baseline measurements included peripapillary retinal nerve fibre layer optical coherence tomography (RNFL OCT), and OCT–angiography (OCT-A) for evaluation of the retinal layer thickness and vessel density (VD) parameters. A multifocal visual evoked potential (mfVEP) test, including amplitude and latency, was used to assess the visual pathway function. Finally, cognitive function was evaluated using a battery of neuropsychological tests. OCT-A images were analysed in ImageJ to quantify VD in the superficial and deep vascular plexus and the size of the foveal avascular zone (FAZ). The relationship between carriers of APOE ε4 allele and these ocular parameters was analysed using generalised estimating equation (GEE) models and data adjusted for age, sex and inter-eye differences as within-subject variables (p < 0.05). Results: Twenty-four participants were APOE ε4 carriers. Temporal RNFL thickness was decreased in APOE ε4 carriers (p < 0.01). Vessel density between carriers and non-carriers was not significantly different at either the superficial or deep level. The FAZ area was significantly smaller in ε4 carriers in both superficial (p < 0.01) and deep layers (p < 0.003). Conclusions: Retinal abnormalities were present in participants with increased genetic risk of dementia due to presence of the ε4 allele. These findings provide preliminary evidence for their potential role in the diagnosis of dementia.

2 July 2025 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
SSSamran Sheriff
Samran Sheriff
MVMaryam Vizheh
Maryam Vizheh
RPRomika Patel
Romika Patel
SSSamantha Spanos
Samantha Spanos
KLKlay Lamprell
Klay Lamprell
JLJanet C. Long
Janet C. Long
The integration of genetic testing into primary care is influencing healthcare practices, yet little is known about consumers’ knowledge, attitudes, and experiences with genetic testing services or the practitioners who provide them. This systematic review synthesizes peer-reviewed studies on consumers’ perspectives regarding the role of primary health professionals in delivering genomic medicine in primary care settings. Six databases (PubMed, Scopus, Embase, CINAHL, Cochrane Library and PsycINFO) were systematically searched. Inclusion criteria focused on studies that addressed consumers’ knowledge, attitudes, and experiences related to Primary Care Providers’ (PCP) roles in genomic medicine. Data relevant to the review objective, including key article characteristics, barriers and facilitators of implementation, and recommendations for advancement or optimisation, were extracted and analysed using thematic analysis. We reviewed 19 studies meeting the inclusion criteria involving 3557 participants. Thematic analysis identified two overarching themes: consumer views on genomic testing irrespective of setting, comprising three sub-themes, and consumer views on genomic testing in the primary care setting, comprising four sub-themes. Consumers’ trust in PCPs as familiar and approachable professionals was a major concern. Consumers often reported positive experiences when PCPs were well-informed and communicative, but negative experiences were common when there was a perceived lack of knowledge or confidence from the PCP. As reported in other healthcare settings, concerns about privacy, data security, and the cost of genomic testing were also prominent. Integrating genomic medicine into primary care requires trust-building between PCPs and consumers, enhancing PCP education and resources, addressing privacy and cost concerns and strengthening collaboration with genetic specialists to improve consumer experiences.

11 September 2026 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
MVMaryam Vizheh
Maryam Vizheh
SSSamran Sheriff
Samran Sheriff
KLKlay Lamprell
Klay Lamprell
RPRomika Patel
Romika Patel
JBJeffrey Braithwaite
Jeffrey Braithwaite
JLJanet C. Long
Janet C. Long
As genomic testing moves into mainstream healthcare, non-genetic healthcare professionals, including general practitioners (GPs), play a critical role as gatekeepers to genetic services. Laboratories are essential in supporting this transition by providing not only high-quality genetic tests but also point-of-care tools, educational materials and clinical guidance to support their use. This study aimed to explore how these tools and supports are conceptualized, developed, implemented and evaluated and how laboratories integrate them into their relationships with GPs, an essential process for paving the way toward better use of genomics in primary care. A qualitative study design was employed using semi-structured, in-depth interviews with representatives from genetic laboratories across Australia. The Consolidated Framework for Implementation Research (CFIR) guided deductive content analysis of data. Findings spanned the four CFIR domains (Intervention Characteristics, Outer Setting, Inner Setting and Implementation Process) across 34 constructs. Participants reported that laboratories viewed point-of-care tools and resources as essential responses to persistent genomic knowledge gaps among GPs. Development of evidence-based, practice-driven and adaptable resources was supported and rewarded within laboratory organisations. A strong culture of clinical responsibility and implementation readiness, combined with robust networks and communications, enabled timely support for GPs. Gaps identified included lack of implementation planning, misalignments between laboratory-developed resources and GPs’ real-world needs and inadequate mechanisms for obtaining GPs’ feedback, which made evaluation problematic. By applying an implementation science framework, these findings provide insights for future efforts to build and sustain the provision of point-of-care tools and support, ultimately improving the integration of genomics in primary care.